VariZIG Market Report 2026

VariZIG Market Overview

• The VariZIG market growth in the historic period has been driven by availability of plasma fractionation technologies, increased awareness of varicella complications • Market expansion is supported by growing demand for immunocompromised patient protection, increasing focus on maternal and neonatal care • Growth Driver: Rising Incidence Of Varicella-Zoster Virus Infections Drives Demand For In High-Risk Populations • Market Trend: Expanding Access Through Multiyear International Supply Contracts • North America was the largest region in 2025.

What Is Covered Under VariZIG Market?

VariZIG is a hyperimmune globulin derived from human plasma with high antibodies against the varicella-zoster virus (VZV). It is used as a post-exposure prophylaxis to reduce the severity of chickenpox in high-risk individuals, such as immunocompromised patients, pregnant women, and newborns. Administered intramuscularly, it provides passive immunity by delivering pre-formed antibodies. Varizig is most effective when given within 96 hours of VZV exposure. The main patient conditions for varizig are immunocompromised patients and pregnant women. Immunocompromised patients have weakened immune systems due to conditions such as HIV, cancer treatments, or immunosuppressive therapy. These are distributed through various distribution channels such as hospitals, pharmacies, and healthcare providers and are used by various end users such as adults, geriatric, and pediatric populations.

What Is The VariZIG Market Growth Forecast?

The growth in the forecast period can be attributed to growing demand for immunocompromised patient protection, increasing focus on maternal and neonatal care, expansion of plasma collection networks, advancements in biologic safety screening, rising investment in preventive immunotherapies. Major trends in the forecast period include increasing use of passive immunization therapies, growing focus on high-risk patient protection, expansion of plasma-derived biologic products, rising emphasis on post-exposure prophylaxis, enhanced cold-chain management practices.

Global VariZIG Market Segmentation

1) By Patient Condition: Immunocompromised Patients, Pregnant Women 2) By Distribution Channel: Hospitals, Pharmacies, Healthcare Providers 3) By End User: Adult, Geriatric, Pediatric

What Are The Drivers Of The VariZIG Market?

The increase in the incidence of varicella-zoster virus infections is expected to drive the varizig market going forward. The varicella-zoster virus (VZV) is a highly contagious virus that causes chickenpox as the primary infection and can reactivate later in life to cause shingles (herpes zoster). The increase in the incidence of varicella-zoster virus (VZV) infections, leading to conditions such as chickenpox and shingles, can be attributed to reduced vaccination rates, an aging population, and immune suppression due to medical treatments. varizig helps varicella-zoster virus patients by providing passive immunity, reducing the severity and duration of chickenpox symptoms, preventing complications in high-risk individuals such as immunocompromised patients, and offering protection against severe outcomes in neonates and pregnant women exposed to the virus. For instance, in November 2024, according to the Florida Department of Health, a US-based government agency, in 2023, the number of varicella cases increased to 653, compared to 428 cases in 2022. Therefore, the rising incidence of varicella-zoster virus infections drives the varizig industry. The rise in healthcare spending is expected to propel the growth of the varizig market going forward. Healthcare spending refers to the total expenditure on health services and products, including medical care, hospital services, preventive care, medications, research, infrastructure, and administrative costs, to maintain or improve the health and well-being of individuals and populations. Healthcare spending is attributed to an aging population, advancements in medical technology, rising prevalence of chronic diseases, and increased demand for healthcare services. Healthcare expenditure supports varizig by allocating funding for the acquisition and distribution of this essential immune globulin, ensuring its availability to high-risk populations, enabling healthcare providers to offer timely treatment for varicella-zoster virus infections, and helping to reduce the overall healthcare burden associated with severe complications from the virus. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare spending is driving the growth of the varizig industry.

Key Players In The Global VariZIG Market

Major companies operating in the varizig market are Emergent BioSolutions Inc.

Global VariZIG Market Trends and Insights

Major companies operating in the VariZIG market are focusing on technological advancement in the form of manufacturing scale-up and advanced distribution logistics, such as contract manufacturing optimisation, regional supply-chain agreements and cold-chain/stability improvements that ensure timely delivery of plasma-derived immunoglobulins to high-need populations. Manufacturing scale-up and distribution logistics refers to the set of process and infrastructure innovations increased production capacity, robust cold-chain and inventory management, regional supply agreements, and coordinated procurement contracts that convert limited specialist biologic products from niche availability into reliable, regionally accessible therapies. For instance, in January 2025, Kamada Ltd., an Israel-based biopharmaceutical company specialising in plasma-derived therapies, announced a $25 million three-year contract to supply KAMRAB and VARIZIG across Latin America from 2025 through 2027. This agreement secures regional supply and reduces the risk of shortages for at-risk patients, enabling hospitals and public health systems to plan prophylaxis and treatment with greater confidence. It also expands commercial access to a previously fragmented market by creating predictable demand and distribution channels across multiple countries, supporting faster patient access. Finally, the contract underpins public-health preparedness for varicella exposure in high-risk groups by ensuring an established supply pathway for an essential passive-immunity product.

Regional Insights

North America was the largest region in the varizig market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the VariZIG Market?

The varizig market consists of sales of pre-filled syringes, injectable solutions, and single-dose vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the VariZIG Market Report 2026?

The varizig market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the varizig industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.